A study compared 4 oral anticoagulant agents apixaban dabigatran rivaroxaban and warfarin for their effects on 4 renal outcomes including 8805 30 decline in estimated glomerular filtration rate eGFR doubling of the serum creatinine level acute kidney injury AKI and kidney failure. The results published in the Journal of the American College of Cardiology demonstrated that renal function decline is common among patients with atrial fibrillation treated with oral anticoagulant agents. Non vitamin K antagonist oral anticoagulant NOACs especially dabigatran and rivaroxaban may be associated with lower risks of adverse renal outcomes than warfarin. The cumulative risk at the end of 2 years was 24.4 4 14.8 and 1.7 for 8805 30 decline in eGFR doubling of serum creatinine AKI and kidney failure respectively.